PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3552262-5	1987	Addition of vanadate to the NaCl solution also induced fingerlike extensions in cells treated with EGF.	Vanadates	12-20	epidermal growth factor	Homo sapiens	99-102	
3552262-7	1987	These findings indicate that Li+, K+, PO4(3-) and vanadate are involved in the processes of EGF-induced morphological changes.	Vanadates	50-58	epidermal growth factor	Homo sapiens	92-95	
3552262-8	1987	Since vanadate and Li+ have been shown to inhibit phosphatases, an EGF-dependent phosphorylation step may play an important role in the induction of the morphological changes observed.	Vanadates	6-14	epidermal growth factor	Homo sapiens	67-70	
7530982-4	1995	Vanadate, a tyrosine phosphatase inhibitor, further potentiated the EGF response, whereas herbimycin A, a tyrosine kinase inhibitor, interfered with it.	Vanadates	0-8	epidermal growth factor	Homo sapiens	68-71	
3877722-3	1985	When phosphatases were inhibited with zinc and vanadate, EGF induced up to 8-fold stimulation of the incorporation of radioactivity from [gamma-32P]ATP into a 35-kDa band on sodium dodecyl sulfate gels.	Vanadates	47-55	epidermal growth factor	Homo sapiens	57-60	
21486282-4	2011	KEY RESULTS: The broad-spectrum PTK inhibitor genistein (10 microM) and the selective epidermal growth factor (EGF) kinase inhibitor AG556 (10 microM) reversibly decreased K(IR) 2.3 current and the effect was reversed by the protein tyrosine phosphatase inhibitor, orthovanadate (1 mM).	Vanadates	265-278	epidermal growth factor	Homo sapiens	111-114	
11745461-10	2001	In the presence of EGF, however, vanadate antagonized EGF action on cell growth and on telomerase activity, and it stimulated spontaneous envelope formation in a dose-dependent manner.	Vanadates	33-41	epidermal growth factor	Homo sapiens	19-22	
11745461-10	2001	In the presence of EGF, however, vanadate antagonized EGF action on cell growth and on telomerase activity, and it stimulated spontaneous envelope formation in a dose-dependent manner.	Vanadates	33-41	epidermal growth factor	Homo sapiens	54-57	
8596488-4	1996	The effect of proteolytically cleaved MIS on reduction of EGF receptor phosphorylation in membrane preparations is decreased by a specific phosphatase inhibitor, vanadate, thus implicating a membrane phosphatase in this MIS action at the EGF receptor.	Vanadates	162-170	epidermal growth factor	Homo sapiens	58-61	
8390452-5	1993	However, MAP kinase can decrease EGF receptor tyrosine phosphorylation through a vanadate-sensitive pathway involving activation of a tyrosine phosphatase.	Vanadates	81-89	epidermal growth factor	Homo sapiens	33-36